Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936297 · ClinicalTrials.gov registry record · NA
Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study
A NA study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02936297 is a NA study that has completed, run by Thomas Jefferson University. The registered enrollment target is 90 participants.
The verdict
NCT02936297, a NA study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
Non-celiac gluten sensitivity (NCGS) is an emerging clinical entity defined as the presence of intestinal and/or extraintestinal symptoms induced by the ingestion or gluten and relieved by a gluten free diet (GFD) in patients without celiac disease or wheat allergy. The pathologic mechanism of the disorder is unknown, and there are no known biomarkers or associated histopathologic findings. In this prospective, randomized controlled trail, we are investigating the utility of patient reported symptom questionnaires, as well as stool gluten and urine quantification tools in patients with NCGS and healthy controls.
Interventions
- DIETARY_SUPPLEMENT High dose Gluten
- DIETARY_SUPPLEMENT Low dose Gluten
- DIETARY_SUPPLEMENT Lactose free placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02936297
The ClinicalTrials.gov registry entry for NCT02936297 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which High dose Gluten is the first listed.
NCT02936297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02936297 about?
NCT02936297 is a clinical study titled "Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study". Non-celiac gluten sensitivity (NCGS) is an emerging clinical entity defined as the presence of intestinal and/or extraintestinal symptoms induced by the ingestion or gluten and relieved by a gluten free diet (GFD) in patients without celiac disease or wheat allergy. The pathologic mechanism of the d...
What is the current status of trial NCT02936297?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2016-06. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02936297?
The interventions under investigation include: High dose Gluten (DIETARY_SUPPLEMENT), Low dose Gluten (DIETARY_SUPPLEMENT), Lactose free placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02936297?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.